Zenagamtide
Sponsors
Novo Nordisk A/S
Conditions
Cardiovascular RiskObesityOverweightType 2 Diabetes
Phase 1
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
RecruitingNCT07855133
Start: 2026-10-05End: 2028-09-06Target: 60Updated: 2026-10-16
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
RecruitingNCT07868354
Start: 2026-10-08End: 2028-09-07Target: 60Updated: 2026-10-16
Phase 3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
RecruitingNCT07668414
Start: 2026-09-22End: 2028-10-10Target: 650Updated: 2026-09-28
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
Not yet recruitingNCT07668401
Start: 2027-01-07End: 2029-01-11Target: 400Updated: 2026-08-24
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
RecruitingNCT07720271
Start: 2026-08-31End: 2028-08-22Target: 950Updated: 2026-09-28
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
RecruitingNCT07797335
Start: 2026-08-24End: 2028-09-20Target: 1778Updated: 2026-09-01
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
Not yet recruitingNCT07861100
Start: 2026-10-26End: 2030-09-16Target: 8500Updated: 2026-10-06